|
1
|
Seyfried TN and Huysentruyt LC: On the
origin of cancer metastasis. Crit Rev Oncog. 18:43–73. 2013.
View Article : Google Scholar
|
|
2
|
Harbeck N, Penault-Llorca F, Cortes J,
Gnant M, Houssami N, Poortmans P, Ruddy K, Tsang J and Cardoso F:
Breast cancer. Nat Rev Dis Primers. 5:662019. View Article : Google Scholar
|
|
3
|
Nowicki TS, Hu-Lieskovan S and Ribas A:
Mechanisms of resistance to PD-1 and PD-L1 blockade. Cancer J.
24:47–53. 2018. View Article : Google Scholar
|
|
4
|
Ju X, Zhang H, Zhou Z and Wang Q:
Regulation of PD-L1 expression in cancer and clinical implications
in immunotherapy. Am J Cancer Res. 10:1–11. 2020.
|
|
5
|
Feng Y, Spezia M, Huang S, Yuan C, Zeng Z,
Zhang L, Ji X, Liu W, Huang B, Luo W, et al: Breast cancer
development and progression: Risk factors, cancer stem cells,
signaling pathways, genomics, and molecular pathogenesis. Genes
Dis. 5:77–106. 2018. View Article : Google Scholar
|
|
6
|
Zhang Z, Zhou L, Xie N, Nice EC, Zhang T,
Cui Y and Huang C: Overcoming cancer therapeutic bottleneck by drug
repurposing. Signal Transduct Target Ther. 5:1132020. View Article : Google Scholar
|
|
7
|
Li CJ, Liao WT, Wu MY and Chu PY: New
insights into the role of autophagy in tumor immune
microenvironment. Int J Mol Sci. 18:15662017. View Article : Google Scholar
|
|
8
|
Schreiber RD, Old LJ and Smyth MJ: Cancer
immunoediting: Integrating immunitys roles in cancer suppression
and promotion. Science. 331:1565–1570. 2011. View Article : Google Scholar
|
|
9
|
Couzin-Frankel J: Breakthrough of the year
2013. Cancer immunotherapy. Science. 342:1432–1433. 2013.
View Article : Google Scholar
|
|
10
|
Dong Y, Sun Q and Zhang X: PD-1 and its
ligands are important immune checkpoints in cancer. Oncotarget.
8:2171–2186. 2017. View Article : Google Scholar
|
|
11
|
Matsushita M and Kawaguchi M:
Immunomodulatory effects of drugs for effective cancer
immunotherapy. J Oncol. 2018:86534892018. View Article : Google Scholar
|
|
12
|
Lin SC, Chu PY, Liao WT, Wu MY, Tsui KH,
Lin LT, Huang CH, Chen LL and Li CJ: Glycyrrhizic acid induces
human MDA-MB-231 breast cancer cell death and autophagy via the
ROS-mitochondrial pathway. Oncol Rep. 39:703–710. 2018.
|
|
13
|
Song Y, He L, Wang Y, Wu Q and Huang W:
Molecularly targeted therapy and immunotherapy for hormone
receptor-positive/human epidermal growth factor receptor 2-negative
advanced breast cancer (review). Oncol Rep. 44:3–13. 2020.
|
|
14
|
Chew V, Toh HC and Abastado JP: Immune
microenvironment in tumor progression: Characteristics and
challenges for therapy. J Oncol. 2012:6084062012. View Article : Google Scholar
|
|
15
|
Chen SN, Chang R, Lin LT, Chern CU, Tsai
HW, Wen ZH, Li YH, Li CJ and Tsui KH: MicroRNA in ovarian cancer:
Biology, pathogenesis, and therapeutic opportunities. Int J Environ
Res Public Health. 16:15102019. View Article : Google Scholar
|
|
16
|
Li YT, Lee WL and Tsui KH: Endometrial
thickness still presents a best reference to predict endometrial
cancer. Taiwan J Obstet Gynecol. 55:148–149. 2016. View Article : Google Scholar
|
|
17
|
Wu MY, Yiang GT, Cheng PW, Chu PY and Li
CJ: Molecular targets in hepatocarcinogenesis and implications for
therapy. J Clin Med. 7:2132018. View Article : Google Scholar
|
|
18
|
Xia A, Zhang Y, Xu J, Yin T and Lu XJ: T
cell dysfunction in cancer immunity and immunotherapy. Front
Immunol. 10:17192019. View Article : Google Scholar
|
|
19
|
Mahoney KM, Rennert PD and Freeman GJ:
Combination cancer immunotherapy and new immunomodulatory targets.
Nat Rev Drug Discov. 14:561–584. 2015. View
Article : Google Scholar
|
|
20
|
Roncati L: Microsatellite instability
predicts response to anti-PD1 immunotherapy in metastatic melanoma.
Acta Dermatovenerol Croat. 26:341–343. 2018.
|
|
21
|
Ribas A: Tumor immunotherapy directed at
PD-1. N Engl J Med. 366:2517–2519. 2012. View Article : Google Scholar
|
|
22
|
Okazaki T and Honjo T: The PD-1-PD-L
pathway in immunological tolerance. Trends Immunol. 27:195–201.
2006. View Article : Google Scholar
|
|
23
|
Sun H, Sun C and Xiao W: Expression
regulation of co-inhibitory molecules on human natural killer cells
in response to cytokine stimulations. Cytokine. 65:33–41. 2014.
View Article : Google Scholar
|
|
24
|
Hirsch I, Janovec V, Stranska R and
Bendriss-Vermare N: Cross talk between inhibitory immunoreceptor
tyrosine-based activation motif-signaling and toll-like receptor
pathways in macrophages and dendritic cells. Front Immunol.
8:3942017. View Article : Google Scholar
|
|
25
|
Pedoeem A, Azoulay-Alfaguter I, Strazza M,
Silverman GJ and Mor A: Programmed death-1 pathway in cancer and
autoimmunity. Clin Immunol. 153:145–152. 2014. View Article : Google Scholar
|
|
26
|
Okazaki T and Honjo T: PD-1 and PD-1
ligands: From discovery to clinical application. Int Immunol.
19:813–824. 2007. View Article : Google Scholar
|
|
27
|
Nawaf MG, Ulvmar MH, Withers DR, McConnell
FM, Gaspal FM, Webb GJ, Jones ND, Yagita H, Allison JP and Lane PJ:
Concurrent OX40 and CD30 ligand blockade abrogates the CD4-driven
autoimmunity associated with CTLA4 and PD1 blockade while
preserving excellent anti-CD8 tumor immunity. J Immunol.
199:974–981. 2017. View Article : Google Scholar
|
|
28
|
Homet Moreno B and Ribas A:
Anti-programmed cell death protein-1/ligand-1 therapy in different
cancers. Br J Cancer. 112:1421–1427. 2015. View Article : Google Scholar
|
|
29
|
Chiu HC, Li CJ, Yiang GT, Tsai AP and Wu
MY: Epithelial to mesenchymal transition and cell biology of
molecular regulation in endometrial carcinogenesis. J Clin Med.
8:4392019. View Article : Google Scholar
|
|
30
|
Tsui KH, Chiang AJ and Yu KJ: Urgent
surgical intervention for ruptured ovarian endometrioma. Taiwan J
Obstet Gynecol. 51:3282012. View Article : Google Scholar
|
|
31
|
Dai S, Jia R, Zhang X, Fang Q and Huang L:
The PD-1/PD-Ls pathway and autoimmune diseases. Cell Immunol.
290:72–79. 2014. View Article : Google Scholar
|
|
32
|
Joshi S and Durden DL: Combinatorial
approach to improve cancer immunotherapy: Rational drug design
strategy to simultaneously hit multiple targets to kill tumor cells
and to activate the immune system. J Oncol. 2019:52450342019.
View Article : Google Scholar
|
|
33
|
Zhang M, Yang J, Zhou J, Gao W, Zhang Y,
Lin Y, Wang H, Ruan Z and Ni B: Prognostic Values of
CD38+CD101+PD1+CD8+ T
cells in pancreatic cancer. Immunol Invest. 48:466–479. 2019.
View Article : Google Scholar
|
|
34
|
Nguyen LT and Ohashi PS: Clinical blockade
of PD1 and LAG3-potential mechanisms of action. Nat Rev Immunol.
15:45–56. 2015. View Article : Google Scholar
|
|
35
|
Topalian SL, Hodi FS, Brahmer JR,
Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD,
Sosman JA, Atkins MB, et al: Safety, activity, and immune
correlates of anti-PD-1 antibody in cancer. N Engl J Med.
366:2443–2454. 2012. View Article : Google Scholar
|
|
36
|
Reiss KA, Forde PM and Brahmer JR:
Harnessing the power of the immune system via blockade of PD-1 and
PD-L1: A promising new anticancer strategy. Immunotherapy.
6:459–475. 2014. View Article : Google Scholar
|
|
37
|
Powles T, Eder JP, Fine GD, Braiteh FS,
Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng SL, et
al: MPDL3280A (anti-PD-L1) treatment leads to clinical activity in
metastatic bladder cancer. Nature. 515:558–562. 2014. View Article : Google Scholar
|
|
38
|
Taube JM, Klein A, Brahmer JR, Xu H, Pan
X, Kim JH, Chen L, Pardoll DM, Topalian SL and Anders R:
Association of PD-1, PD-1 ligands, and other features of the tumor
immune microenvironment with response to anti-PD-1 therapy. Clin
Cancer Res. 20:5064–5074. 2014. View Article : Google Scholar
|
|
39
|
Garon EB, Rizvi NA, Hui R, Leighl N,
Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L,
et al: Pembrolizumab for the treatment of non-small-cell lung
cancer. N Engl J Med. 372:2018–2028. 2015. View Article : Google Scholar
|
|
40
|
Koppel C, Schwellenbach H, Zielinski D,
Eckstein S, Martin-Ortega M, D'Arrigo C, Schildhaus HU, Rüschoff J
and Jasani B: Optimization and validation of PD-L1
immunohistochemistry staining protocols using the antibody clone
28-8 on different staining platforms. Mod Pathol. 31:1630–1644.
2018. View Article : Google Scholar
|
|
41
|
Ilie M, Long-Mira E, Bence C, Butori C,
Lassalle S, Bouhlel L, Fazzalari L, Zahaf K, Lalvée S, Washetine K,
et al: Comparative study of the PD-L1 status between surgically
resected specimens and matched biopsies of NSCLC patients reveal
major discordances: A potential issue for anti-PD-L1 therapeutic
strategies. Ann Oncol. 27:147–153. 2016. View Article : Google Scholar
|
|
42
|
Wu Z, Zhang L, Peng J, Xu S, Zhou L, Lin
Y, Wang Y and Lu J, Yin W and Lu J: Predictive and prognostic value
of PDL1 protein expression in breast cancer patients in neoadjuvant
setting. Cancer Biol Ther. 20:941–947. 2019. View Article : Google Scholar
|
|
43
|
Gerlinger M, Rowan AJ, Horswell S, Math M,
Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N,
Stewart A, et al: Intratumor heterogeneity and branched evolution
revealed by multiregion sequencing. N Engl J Med. 366:883–892.
2012. View Article : Google Scholar
|
|
44
|
McLaughlin J, Han G, Schalper KA,
Carvajal-Hausdorf D, Pelekanou V, Rehman J, Velcheti V, Herbst R,
LoRusso P and Rimm DL: Quantitative assessment of the heterogeneity
of PD-L1 expression in non-small-cell lung cancer. JAMA Oncol.
2:46–54. 2016. View Article : Google Scholar
|
|
45
|
Ilie M, Hofman V, Dietel M, Soria JC and
Hofman P: Assessment of the PD-L1 status by immunohistochemistry:
Challenges and perspectives for therapeutic strategies in lung
cancer patients. Virchows Arch. 468:511–525. 2016. View Article : Google Scholar
|
|
46
|
Schalper KA, Velcheti V, Carvajal D,
Wimberly H, Brown J, Pusztai L and Rimm DL: In situ tumor PD-L1
mRNA expression is associated with increased TILs and better
outcome in breast carcinomas. Clin Cancer Res. 20:2773–2782. 2014.
View Article : Google Scholar
|
|
47
|
Mazel M, Jacot W, Pantel K, Bartkowiak K,
Topart D, Cayrefourcq L, Rossille D, Maudelonde T, Fest T and
Alix-Panabières C: Frequent expression of PD-L1 on circulating
breast cancer cells. Mol Oncol. 9:1773–1782. 2015. View Article : Google Scholar
|
|
48
|
Yue C, Jiang Y, Li P, Wang Y, Xue J, Li N,
Li D, Wang R, Dang Y, Hu Z, et al: Dynamic change of PD-L1
expression on circulating tumor cells in advanced solid tumor
patients undergoing PD-1 blockade therapy. Oncoimmunology.
7:e14381112018. View Article : Google Scholar
|
|
49
|
Acheampong E, Spencer I, Lin W, Ziman M,
Millward M and Gray E: Is the blood an alternative for programmed
cell death ligand 1 assessment in non-small cell lung cancer?
Cancers (Basel). 11:9202019. View Article : Google Scholar
|
|
50
|
Marzec M, Zhang Q, Goradia A, Raghunath
PN, Liu X, Paessler M, Wang HY, Wysocka M, Cheng M, Ruggeri BA and
Wasik MA: Oncogenic kinase NPM/ALK induces through STAT3 expression
of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad
Sci USA. 105:20852–20857. 2008. View Article : Google Scholar
|
|
51
|
Tang J, Yu JX, Hubbard-Lucey VM,
Neftelinov ST, Hodge JP and Lin Y: Trial watch: The clinical trial
landscape for PD1/PDL1 immune checkpoint inhibitors. Nat Rev Drug
Discov. 17:854–855. 2018. View Article : Google Scholar
|
|
52
|
Holz MK: The role of S6K1 in ER-positive
breast cancer. Cell Cycle. 11:3159–3165. 2012. View Article : Google Scholar
|
|
53
|
Sridharan S and Basu A: Distinct roles of
mTOR targets S6K1 and S6K2 in breast cancer. Int J Mol Sci.
21:11992020. View Article : Google Scholar
|
|
54
|
Crane CA, Panner A, Murray JC, Wilson SP,
Xu H, Chen L, Simko JP, Waldman FM, Pieper RO and Parsa AT: PI(3)
kinase is associated with a mechanism of immunoresistance in breast
and prostate cancer. Oncogene. 28:306–312. 2009. View Article : Google Scholar
|
|
55
|
Jiang X, Zhou J, Giobbie-Hurder A, Wargo J
and Hodi FS: The activation of MAPK in melanoma cells resistant to
BRAF inhibition promotes PD-L1 expression that is reversible by MEK
and PI3K inhibition. Clin Cancer Res. 19:598–609. 2013. View Article : Google Scholar
|
|
56
|
Ghebeh H, Lehe C, Barhoush E, Al-Romaih K,
Tulbah A, Al-Alwan M, Hendrayani SF, Manogaran P, Alaiya A,
Al-Tweigeri T, et al: Doxorubicin downregulates cell surface B7-H1
expression and upregulates its nuclear expression in breast cancer
cells: Role of B7-H1 as an anti-apoptotic molecule. Breast Cancer
Res. 12:R482010. View Article : Google Scholar
|
|
57
|
Peng J, Hamanishi J, Matsumura N, Abiko K,
Murat K, Baba T, Yamaguchi K, Horikawa N, Hosoe Y, Murphy SK, et
al: Chemotherapy induces programmed cell death-ligand 1
overexpression via the nuclear factor-κB to foster an
immunosuppressive tumor microenvironment in ovarian cancer. Cancer
Res. 75:5034–5045. 2015. View Article : Google Scholar
|
|
58
|
Uhercik M, Sanders AJ, Owen S, Davies EL,
Sharma AK, Jiang WG and Mokbel K: Clinical significance of PD1 and
PDL1 in human breast cancer. Anticancer Res. 37:4249–4254.
2017.
|
|
59
|
Twyman-Saint Victor C, Rech AJ, Maity A,
Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi
PM, et al: Radiation and dual checkpoint blockade activate
non-redundant immune mechanisms in cancer. Nature. 520:373–377.
2015. View Article : Google Scholar
|
|
60
|
Lv S, Wang S, Qiao G, Wang X, Zhou X, Yan
F, Li Y, Wang S, Morse MA, Hobeika A, et al: Functional
CD3+CD8+PD1− T cell accumulation
and PD-L1 expression increases during tumor invasion in DCIS of the
breast. Clin Breast Cancer. 19:e617–e623. 2019. View Article : Google Scholar
|
|
61
|
Beckers RK, Selinger CI, Vilain R, Madore
J, Wilmott JS, Harvey K, Holliday A, Cooper CL, Robbins E, Gillett
D, et al: Programmed death ligand 1 expression in triple-negative
breast cancer is associated with tumour-infiltrating lymphocytes
and improved outcome. Histopathology. 69:25–34. 2016. View Article : Google Scholar
|
|
62
|
Mittendorf EA, Philips AV, Meric-Bernstam
F, Qiao N, Wu Y, Harrington S, Su X, Wang Y, Gonzalez-Angulo AM,
Akcakanat A, et al: PD-L1 expression in triple-negative breast
cancer. Cancer Immunol Res. 2:361–370. 2014. View Article : Google Scholar
|
|
63
|
Gatalica Z, Snyder C, Maney T, Ghazalpour
A, Holterman DA, Xiao N, Overberg P, Rose I, Basu GD, Vranic S, et
al: Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common
cancers and their correlation with molecular cancer type. Cancer
Epidemiol Biomarkers Prev. 23:2965–2970. 2014. View Article : Google Scholar
|
|
64
|
Bertucci F, Finetti P, Colpaert C,
Mamessier E, Parizel M, Dirix L, Viens P, Birnbaum D and van Laere
S: PDL1 expression in inflammatory breast cancer is frequent and
predicts for the pathological response to chemotherapy. Oncotarget.
6:13506–13519. 2015. View Article : Google Scholar
|
|
65
|
Sabatier R, Finetti P, Mamessier E,
Adelaide J, Chaffanet M, Ali HR, Viens P, Caldas C, Birnbaum D and
Bertucci F: Prognostic and predictive value of PDL1 expression in
breast cancer. Oncotarget. 6:5449–5464. 2015. View Article : Google Scholar
|
|
66
|
Muenst S, Schaerli AR, Gao F, Däster S,
Trella E, Droeser RA, Muraro MG, Zajac P, Zanetti R, Gillanders WE,
et al: Expression of programmed death ligand 1 (PD-L1) is
associated with poor prognosis in human breast cancer. Breast
Cancer Res Treat. 146:15–24. 2014. View Article : Google Scholar
|
|
67
|
Muenst S, Soysal SD, Gao F, Obermann EC,
Oertli D and Gillanders WE: The presence of programmed death 1
(PD-1)-positive tumor-infiltrating lymphocytes is associated with
poor prognosis in human breast cancer. Breast Cancer Res Treat.
139:667–676. 2013. View Article : Google Scholar
|
|
68
|
Sun S, Fei X, Mao Y, Wang X, Garfield DH,
Huang O, Wang J, Yuan F, Sun L, Yu Q, et al: PD-1(+) immune cell
infiltration inversely correlates with survival of operable breast
cancer patients. Cancer Immunol Immunother. 63:395–406. 2014.
View Article : Google Scholar
|
|
69
|
Pardoll DM: The blockade of immune
checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264.
2012. View Article : Google Scholar
|
|
70
|
Hasan A, Ghebeh H, Lehe C, Ahmad R and
Dermime S: Therapeutic targeting of B7-H1 in breast cancer. Expert
Opin Ther Targets. 15:1211–1225. 2011. View Article : Google Scholar
|
|
71
|
Lipson EJ, Forde PM, Hammers HJ, Emens LA,
Taube JM and Topalian SL: Antagonists of PD-1 and PD-L1 in cancer
treatment. Semin Oncol. 42:587–600. 2015. View Article : Google Scholar
|
|
72
|
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ,
Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al:
Safety and activity of anti-PD-L1 antibody in patients with
advanced cancer. N Engl J Med. 366:2455–2465. 2012. View Article : Google Scholar
|
|
73
|
Wang Y, Zhang X, Yang L, Xue J and Hu G:
Blockade of CCL2 enhances immunotherapeutic effect of anti-PD1 in
lung cancer. J Bone Oncol. 11:27–32. 2018. View Article : Google Scholar
|
|
74
|
Stenehjem DD, Tran D, Nkrumah MA and Gupta
S: PD1/PDL1 inhibitors for the treatment of advanced urothelial
bladder cancer. Onco Targets Ther. 11:5973–5989. 2018. View Article : Google Scholar
|
|
75
|
Wagner MJ, Ricciotti RW, Mantilla J,
Loggers ET, Pollack SM and Cranmer LD: Response to PD1 inhibition
in conventional chondrosarcoma. J Immunother Cancer. 6:942018.
View Article : Google Scholar
|
|
76
|
Neubert NJ, Schmittnaegel M, Bordry N,
Nassiri S, Wald N, Martignier C, Tillé L, Homicsko K, Damsky W,
Maby-El Hajjami H, et al: T cell-induced CSF1 promotes melanoma
resistance to PD1 blockade. Sci Transl Med. 10:eaan33112018.
View Article : Google Scholar
|
|
77
|
Pusztai L, Karn T, Safonov A, Abu-Khalaf
MM and Bianchini G: New strategies in breast cancer: Immunotherapy.
Clin Cancer Res. 22:2105–2110. 2016. View Article : Google Scholar
|
|
78
|
Nanda R, Chow LQM, Dees EC, Berger R,
Gupta S, Geva R, Pusztai L, Pathiraja K, Aktan G, Cheng JD, et al:
Pembrolizumab in patients with advanced triple-negative breast
cancer: phase Ib KEYNOTE-012 study. J Clin Oncol. 34:2460–2467.
2016. View Article : Google Scholar
|
|
79
|
Emens LA: Breast cancer immunobiology
driving immunotherapy: Vaccines and immune checkpoint blockade.
Expert Rev Anticancer Ther. 12:1597–1611. 2012. View Article : Google Scholar
|
|
80
|
Badr NM, Berditchevski F and Shaaban AM:
The immune microenvironment in breast carcinoma: Predictive and
prognostic role in the neoadjuvant setting. Pathobiology. 87:61–74.
2020. View Article : Google Scholar
|
|
81
|
Tan W, Yang M, Yang H, Zhou F and Shen W:
Predicting the response to neoadjuvant therapy for early-stage
breast cancer: Tumor-, blood-, and imaging-related biomarkers.
Cancer Manag Res. 10:4333–4347. 2018. View Article : Google Scholar
|
|
82
|
Loi S, Dushyanthen S, Beavis PA, Salgado
R, Denkert C, Savas P, Combs S, Rimm DL, Giltnane JM, Estrada MV,
et al: RAS/MAPK activation is associated with reduced
tumor-infiltrating lymphocytes in triple-negative breast cancer:
Therapeutic cooperation between MEK and PD-1/PD-L1 immune
checkpoint inhibitors. Clin Cancer Res. 22:1499–1509. 2016.
View Article : Google Scholar
|
|
83
|
Sagiv-Barfi I, Kohrt HE, Czerwinski DK, Ng
PP, Chang BY and Levy R: Therapeutic antitumor immunity by
checkpoint blockade is enhanced by ibrutinib, an inhibitor of both
BTK and ITK. Proc Natl Acad Sci USA. 112:E966–E972. 2015.
View Article : Google Scholar
|
|
84
|
Garcia-Aranda M and Redondo M:
Immunotherapy: A challenge of breast cancer treatment. Cancers
(Basel). 11:18222019. View Article : Google Scholar
|
|
85
|
Chawla A, Philips AV, Alatrash G and
Mittendorf E: Immune checkpoints: A therapeutic target in triple
negative breast cancer. Oncoimmunology. 3:e283252014. View Article : Google Scholar
|
|
86
|
Chatterjee S, Lesniak WG, Gabrielson M,
Lisok A, Wharram B, Sysa-Shah P, Azad BB, Pomper MG and Nimmagadda
S: A humanized antibody for imaging immune checkpoint ligand PD-L1
expression in tumors. Oncotarget. 7:10215–10227. 2016. View Article : Google Scholar
|
|
87
|
Herbst RS, Soria JC, Kowanetz M, Fine GD,
Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger
SN, et al: Predictive correlates of response to the anti-PD-L1
antibody MPDL3280A in cancer patients. Nature. 515:563–567. 2014.
View Article : Google Scholar
|
|
88
|
Tumeh PC, Harview CL, Yearley JH, Shintaku
IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu
V, et al: PD-1 blockade induces responses by inhibiting adaptive
immune resistance. Nature. 515:568–571. 2014. View Article : Google Scholar
|
|
89
|
Gibson J: Anti-PD-L1 for metastatic
triple-negative breast cancer. Lancet Oncol. 16:e2642015.
View Article : Google Scholar
|
|
90
|
Ott PA, Hodi FS and Robert C: CTLA-4 and
PD-1/PD-L1 blockade: New immunotherapeutic modalities with durable
clinical benefit in melanoma patients. Clin Cancer Res.
19:5300–5309. 2013. View Article : Google Scholar
|
|
91
|
Kerr KM and Hirsch FR: Programmed death
ligand-1 immunohistochemistry: Friend or foe? Arch Pathol Lab Med.
140:326–331. 2016. View Article : Google Scholar
|
|
92
|
Voutsadakis IA: Immune blockade inhibition
in breast cancer. Anticancer Res. 36:5607–5622. 2016. View Article : Google Scholar
|
|
93
|
Yi KH and Chen L: Fine tuning the immune
response through B7-H3 and B7-H4. Immunol Rev. 229:145–151. 2009.
View Article : Google Scholar
|
